GlassScriptPhysician profile
Chawki Harfouch
NPI 1942462783
$6,858.96
in general payments reported to CMS, 2019-2025
21 companies · $815 in 2025
The $815 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $802 · 2020: $445 · 2021: $679 · 2022: $1,090 · 2023: $1,349 · 2024: $1,678 · 2025: $815.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,842.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,841.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $3,169.31 | 2019-2025 | Cabenuva, Dovato, Rukobia |
| Gilead Sciences, INC. | $634.97 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $609.45 | 2019-2025 | Recarbrio, Dificid, Pifeltro |
| Abbvie INC. | $443.62 | 2021-2025 | |
| Insmed, INC. | $374.43 | 2019-2025 | Arikayce |
| Astellas Pharma US INC | $324.46 | 2019-2024 | Cresemba |
| Theratechnologies INC. | $322.18 | 2021-2024 | Trogarzo, Egrifta |
| Cumberland Pharmaceuticals, INC. | $237.15 | 2019-2023 | Vibativ |
| Shionogi INC | $202.55 | 2022-2025 | Fetroja |
| Paratek Pharmaceuticals, INC. | $150.85 | 2021-2024 | Nuzyra |
| Aimmune Therapeutics, INC. | $109.90 | 2023 | |
| La Jolla Pharmaceutical Company | $71.13 | 2022-2025 | Xacduro, Xerava |
| Janssen Biotech, INC. | $40.22 | 2022-2023 | Symtuza |
| Grt US Holding, INC. | $34.75 | 2022 | |
| Tetraphase Pharmaceuticals, INC. | $33.42 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $23.10 | 2020 | |
| Ferring Pharmaceuticals INC. | $20.25 | 2023 | Rebyota |
| Octapharma USA, INC. | $18.44 | 2024 | Panzyga |
| Grifols USA, LLC | $16.25 | 2024 | Gamunex-C |
| Allergan, INC. | $11.32 | 2020 | |
| Janssen Pharmaceuticals, INC | $11.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chawki Harfouch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.